FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors

LONDON , Jan. 2, 2023. Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted ' Breakthrough Device Designation ' for its ' TriNetra-Glio ' , a blood test to help in the diagnosis of brain tumors. This is the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials